These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 38217945)

  • 21. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
    Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
    BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
    Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
    Sobrero A; Lenz HJ; Eng C; Scheithauer W; Middleton G; Chen W; Esser R; Nippgen J; Burris H
    Oncologist; 2021 Feb; 26(2):e261-e269. PubMed ID: 33191588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. China special issue on gastrointestinal tumors-Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study.
    Quan M; Chen J; Chen Z; Hai Y; Zhou Y; Chao Q; Chen C; Li H; Wang M; Gao Y
    Int J Cancer; 2023 Dec; 153(11):1877-1884. PubMed ID: 37163613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
    Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
    Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
    Osumi H; Shinozaki E; Mashima T; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Ota Y; Nakayama I; Takahari D; Chin K; Miki Y; Yamaguchi K
    Cancer Sci; 2018 Aug; 109(8):2567-2575. PubMed ID: 29908105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
    Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
    Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
    Lonardi S; Rasola C; Lobefaro R; Rossini D; Formica V; Scartozzi M; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Pella N; Bergamo F; Raimondi A; Arnoldi E; Antonuzzo L; Granetto C; Zustovich F; Ronzoni M; Leo S; Morano F; Loupakis F; Buggin F; Zagonel V; Fassan M; Cremolini C; Boni L; Pietrantonio F;
    J Clin Oncol; 2023 Dec; 41(34):5263-5273. PubMed ID: 37535876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
    Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M
    Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC; Ning JY; Chen HB
    Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Elez E; Pericay C; Valladares-Ayerbes M; Bando I; Safont MJ; Gallego J; Grávalos C; Arrivi A; Carrato A; Conde V; Ortiz MJ; López C; Alonso B; Ruiz de Mena I; Díaz-Rubio E; Tabernero J; Aranda E
    Br J Cancer; 2019 Aug; 121(5):378-383. PubMed ID: 31363167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group.
    Salgado Fernández M; Reboredo López M; Covela Rúa M; Candamio S; González-Villarroel P; Sánchez-Cousido LF; Graña B; Carral-Maseda A; Cameselle-García S; Varela Pose V; Gallardo-Martín ME; Martínez-Lago N;
    Target Oncol; 2024 Jul; 19(4):565-573. PubMed ID: 38780742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
    Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
    Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
    Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
    Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
    Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.